<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="176384">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799383</url>
  </required_header>
  <id_info>
    <org_study_id>K23MH085005</org_study_id>
    <secondary_id>K23MH085005</secondary_id>
    <nct_id>NCT00799383</nct_id>
  </id_info>
  <brief_title>Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia</brief_title>
  <official_title>Counteracting Risperidone-Induced Hyperprolactinemia in Youths</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Miracle Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether calcium and vitamin D supplementation,
      over a nine-month period, optimizes bone mineralization in boys with risperidone-induced
      hyperprolactinemia. We hypothesize that, by the end of the stuy, children in the
      supplementation group will have higher bone mineral density compared to those in the placebo
      group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trabecular bone mineral density in the ultradistal radius</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total body bone mineral content</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Risperidone-induced Hyperprolactinemia</condition>
  <arm_group>
    <arm_group_label>Calcium+VitD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium and Vitamin D</intervention_name>
    <description>Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
I labelled the intervention type as &quot;drug&quot;, even though &quot;dietary supplement&quot; would be more appropriate as the system sent the following error message:
ERROR: An IND/IDE study must have at least one intervention of type: Drug, Device, Biological/Vaccine, Radiation or Genetic.</description>
    <arm_group_label>Calcium+VitD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males (age range: 5-17yo; inclusive), in treatment with risperidone for ≥ one year.

          2. The participants must have two measurements of prolactin ≥ 18.4 ng/ml, obtained
             within a week.

          3. IQ &gt; 35-40 (≥ Moderate intellectual disability).

          4. An adult parent/guardian must be available to provide consent and dispense study
             medication.

        Exclusion Criteria:

          1. Chronic disorders involving a vital organ (heart, lung, liver, kidney, brain),
             metabolic diseases (e.g., diabetes, hypo- or hyperparathyroidism, hypo- or
             hyperthyroidism, growth hormone deficiency), other skeletal diseases (e.g., Paget's
             disease, osteogenesis imperfecta, rheumatoid arthritis), chronic use of drugs
             affecting bone metabolism (e.g., corticosteroids), and malnutrition conditions (e.g.,
             chronic diarrhea, inflammatory bowel disease), congenital disorders, or lead
             poisoning.

          2. Participants receiving calcium or multivitamins in the previous three months.

          3. A history of renal calculi and fasting random urine calcium/creatinine ratio &gt; 0.2 or
             any other medical disorder that contraindicates the use of calcium or vitamin D
             (e.g., hypercalcemic states, hypercoagulability disorders, vitamin D toxicity,
             malabsorption syndrome, or hypersensitivity to vitamin D products).

          4. Laboratory values outside the normal range, except for prolactin, unless the
             deviations were not clinically significant (e.g. TSH &lt; 10 μIU/ml (76)).

          5. Inability to cooperate with the BMD measurements.

          6. Bilateral wrist or forearm fractures.

          7. Eating disorders.

          8. Non-compliance with the prescribed psychiatric treatment as reflected by an
             undetectable combined risperidone and 9-hydroxy risperidone blood concentration.

          9. Plans to move out of State within the next 9 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chadi Calarge, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>November 25, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Risperidone</keyword>
  <keyword>hyperprolactinemia</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>prevention</keyword>
  <keyword>calcium</keyword>
  <keyword>vitamin D</keyword>
  <keyword>Risperidone-induced hyperprolactinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperprolactinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
